SCHEMBL7029

SCHEMBL7029

CCOC(=O)C(C)c1ccc(Br)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 3/20 0.49
CYP2D6 P10635 1/20 0.49
TSHR P16473 1/20 0.49
MEN1 O00255 2/20 0.47
MAPT P10636 2/20 0.47
KMT2A Q03164 2/20 0.47
S1PR4 O95977 1/20 0.47
LMNA P02545 1/20 0.47
S1PR1 P21453 1/20 0.47
MAPK1 P28482 1/20 0.47
NPSR1 Q6W5P4 1/20 0.47
HTT P42858 1/20 0.43
KDM4E B2RXH2 2/20 0.43
GAA P10253 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
MMP8 P22894 1/20 0.42
NPC1 O15118 1/20 0.42
CYP2C9 P11712 1/20 0.42
CYP2C19 P33261 1/20 0.42
RECQL P46063 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28410583 0.85 FFAR1 (0.51) TSHRLMNANPSR1CYP2C9L3MBTL1
SCHEMBL3279844 0.85 KMT2A (0.47) TSHRMEN1KMT2ALMNAHTT
SCHEMBL20930834 0.85 KMT2A (0.50) CYP1A2MEN1MAPTKMT2AS1PR4
SCHEMBL31198054 0.84 MAPT (0.46) CYP1A2MEN1MAPTKMT2AS1PR4
SCHEMBL536847 0.83 MMP8 (0.56) CYP1A2TSHRMEN1MAPTKMT2A
SCHEMBL11598177 0.83 LMNA (0.49) CYP1A2CYP2D6MEN1MAPTKMT2A
SCHEMBL1792502 0.83 ESR1 (0.53) CYP1A2CYP2D6TSHRMAPTKMT2A
SCHEMBL9235662 0.83 ESR1 (0.53) CYP1A2CYP2D6TSHRMAPTKMT2A
SCHEMBL9232941 0.83 ESR1 (0.53) CYP1A2CYP2D6TSHRMAPTKMT2A
SCHEMBL20564825 0.82 KMT2A (0.45) CYP1A2MEN1MAPTKMT2AS1PR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 162 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113980117-B Fenpyroximate antigen and preparation method and application thereof 西南大学 2024-07-12 CN claimed
CN-117820460-A Methoxypiperidine ethyl antigen and preparation method and application thereof 西南大学 2024-04-05 CN claimed
CN-116425739-A Compound for tumor targeted imaging and photodynamic therapy and synthesis method and application thereof 浙江义氪生物科技有限公司 2023-07-14 CN claimed
US-12398089-B2 Method for preparing organic carboxylic ester by using combined catalyst of aryl bidentate phosphine ligand NANJING CHENGZHI CLEAN ENERGY CO. LTD. (CN) 2025-08-26 US disclosed
CN-118955244-A Method for preparing primary alcohol by homogeneously catalyzing and reducing carboxylic acid derivative by using N-heterocyclic carbene copper complex 延安大学 2024-11-15 CN disclosed
CN-116425739-B Compound for tumor targeted imaging and photodynamic therapy and synthesis method and application thereof 浙江义氪生物科技有限公司 2024-08-20 CN disclosed
CN-113980117-B Fenpyroximate antigen and preparation method and application thereof 西南大学 2024-07-12 CN disclosed
CN-118063326-A Method for promoting nickel catalysis to synthesize arylamine compound by red light 陕西师范大学 2024-05-24 CN disclosed
CN-117820460-A Methoxypiperidine ethyl antigen and preparation method and application thereof 西南大学 2024-04-05 CN disclosed
CN-116425739-A Compound for tumor targeted imaging and photodynamic therapy and synthesis method and application thereof 浙江义氪生物科技有限公司 2023-07-14 CN disclosed
EP-3442977-B1 INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE BLUEPRINT MEDICINES CORP (US) 2023-06-28 EP disclosed
US-7432261-B2 Anti-inflammatory phosphonate compounds GILEAD SCIENCES, INC. (US) 2008-10-07 US disclosed
EP-1971582-A1 MACROCYCLIC FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS Brystol-Myers Squibb Company (US) 2008-09-24 EP disclosed
US-20070213311-A1 Modulators of 11-beta hydroxyl steroid dehydrogenase type 1, pharmaceutical compositions thereof, and methods of using the same INCYTE CORPORATION 2007-09-13 US disclosed
WO-2007101270-A1 MODULATORS OF 11-β HYDROXYL STEROID DEHYDROGENASE TYPE 1, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME INCYTE CORPORATION (US) 2007-09-07 WO disclosed
US-20070208054-A1 MACROCYCLIC FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS BRISTOL-MYERS SQUIBB COMPANY 2007-09-06 US disclosed
US-20070208054-A1 MACROCYCLIC FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS BRISTOL-MYERS SQUIBB COMPANY 2007-09-06 US disclosed
US-20070208054-A1 MACROCYCLIC FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS BRISTOL-MYERS SQUIBB COMPANY 2007-09-06 US disclosed
WO-2007076431-A1 MACROCYCLIC FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS BRISTOL-MYERS SQUIBB COMPANY (US) 2007-07-05 WO disclosed
WO-2007076431-A1 MACROCYCLIC FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS BRISTOL-MYERS SQUIBB COMPANY (US) 2007-07-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070213311-A1 Modulators of 11-beta hydroxyl steroid dehydrogenase type 1, pharmaceutical compositions thereof, and methods of using the same HSD11B1, HSD17B1, HSD3B1 CYP1A2 114/4885CYP2D6 219/4885TSHR 3673/4885
US-12398089-B2 Method for preparing organic carboxylic ester by using combined catalyst of aryl bidentate phosphine ligand POF1B, ADH1C, OSBP CYP1A2 254/4885CYP2D6 192/4885TSHR 2891/4885
US-20070208054-A1 MACROCYCLIC FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS F12, F7, F2 CYP1A2 873/4885CYP2D6 449/4885TSHR 799/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.